logo

tagline

About us

A brief history of the Hepatitis B&C Public Policy Association

In April 2009, a group of leading European scientists, public health experts and patient advocates created the Hepatitis B and C Summit Conferences Association as a Luxembourg-based not-for-profit Association.

The aim of the association is to urge and facilitate the formulation of public policies at national and international level for the communication, prevention and management of the spread of viral Hepatitis B and C. The Association’s unique approach in furtherance of this aim is to gather together, and work in partnership with, the major stakeholders in the field of these diseases including regulators, patients, clinicians, public health and civil society communities and the private sector.

In the beginning, the Association aimed primarily to deliver a summit conference on Hepatitis B and C in Europe, which was held in Brussels in October 2010 under the auspices of the Belgian EU Presidency. A call-to-action followed this meeting.

Since then the Hepatitis B & C Public Policy Association has hosted another two major meetings. The Conference on Hepatitis B and C in Mediterranean and Balkan Countries was held on 5th-7th December, 2012 in Nicosia, Cyprus under the auspices of the Cyprus EU Presidency. This Conference addressed the urgent need to prevent, diagnose and treat viral hepatitis B and C in Mediterranean and Balkan countries where the burden of these diseases is significant, the Conference presented both new and existing data and permitted targeted discussion with the specific objective of promoting common strategies on their prevention and management.  A call-to-action followed.

The third major event organised by the Hepatitis B&C Public Policy Association was The High Level Meeting  held in Athens, Greece on 3-4 June 2014 under the auspices of the Greek EU Presidency, the Greek Ministry of Health and the Greek Ministry of Foreign Affairs. The meeting addressed the subject of "Economic crisis and healthcare – ensuring access to public health services: the case of hepatitis B and C". The Athens High-Level Meeting examined national approaches, debated new developments and identified public policies to facilitate and improve access to care and treatment for hepatitis B and hepatitis C even in countries where austerity programmes are in place. A call-to-action followed which covered themes such as urging EU to implement specific policies to address barriers related to availability and access to evidence-based knowledge of hepatitis B and C, access to prevention, diagnosis and treatment services, social stigma and discrimination. A call to action followed.

The Association publishes an e- newsletter that is sent to a readership of 4,000 stakeholders four or five times per year. For further information on the Hepatitis B&C Public Policy Association, please consult www.hepbcppa.org

The current members of the Hepatitis B&C Public Policy Association are:
  • Prof M Buti, Spain
  • Dr M Carballo, Switzerland
  • Prof M Colombo, Italy
  • Prof A Craxi, Italy
  • Prof G Esmat, Egypt
  • Prof R Esteban, Spain, Treasurer
  • Dr D Goldberg, UK
  • Mr C Gore, Co-Chair, UK
  • Prof A Hatzakis, Greece, Co-Chair
  • Prof H. Janssen, The Netherlands, Canada
  • Mr A Kautz, Belgium
  • Prof M Manns, Germany, Co-Chair
  • Prof P Marcellin, France
  • Prof M Mathurin, France
  • Prof G Papatheodoridis, Greece
  • Prof M Peck-Radosavljevic, Austria
  • Prof H Thomas, UK, Co-Chair
  • Prof M Thursz, UK
  • Prof N Tozan, Turkey
  • Prof P van Damme, Belgium
  • Prof H Wedemeyer, Germany

With financial support of

Official endorsements